Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€116.80

€116.80

2.370%
2.7
2.370%
€247.17
 
06.06.25 / Tradegate WKN: 789617 / Symbol: BIIB / Name: Biogen / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Biogen Inc. Stock

There is an upward development for Biogen Inc. compared to yesterday, with an increase of €2.70 (2.370%).
With 39 Buy predictions and 1 Sell predictions Biogen Inc. is one of the favorites of our community.
Based on the current price of 116.8 € the target price of 247 € shows a potential of 111.47% for Biogen Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Biogen Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Biogen Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Biogen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Biogen Inc. 2.370% 2.232% 13.729% -45.190% -18.917% -36.947% -57.019%
Elanco Animal Health Inc. 3.580% 2.484% 43.243% -27.209% 5.733% -45.479% -42.406%
Johnson & Johnson 1.240% -0.293% 0.162% 1.130% -2.200% -17.852% 4.262%
Pfizer Inc. 1.480% -0.847% 1.865% -22.586% -19.275% -59.007% -32.333%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-27

Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.

Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.

Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.

Comments

Prediction Buy
Perf. (%) 13.07%
Target price 148.974
Change
Ends at 07.05.26

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $207.00 to $169.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 7.01%
Target price 181.507
Change
Ends at 02.05.26

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Royal Bank of Canada from $217.00 to $205.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 8.20%
Target price 165.570
Change
Ends at 02.05.26

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $241.00 to $187.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

News

Biogen Stock Is Mutating Into a Value Play
Biogen Stock Is Mutating Into a Value Play

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology

Biogen Stock: Mixed Q4 Results Spark Strategic Shift
Biogen Stock: Mixed Q4 Results Spark Strategic Shift

Biogen's fourth quarter 2024 performance presents a complex picture for investors, with revenue climbing 2.9% to $2.46 billion and adjusted earnings per share reaching $3.44, surpassing market

Biogen (BIIB) Q4 2024 Earnings Call Transcript
Biogen (BIIB) Q4 2024 Earnings Call Transcript

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2024 Earnings CallFeb 12, 2025, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com